FLGT vs. CPRX

Last updated Apr 1, 2026

Compare and contrast key facts about Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX).

Performance

FLGT vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

FLGT vs. CPRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
FLGT Fulgent Genetics, Inc.	-39.47%	42.23%	-36.11%	-2.92%	-70.39%	93.07%	303.88%	306.94%	-27.63%	-62.14%
CPRX Catalyst Pharmaceuticals, Inc.	6.08%	11.84%	24.15%	-9.62%	174.74%	102.69%	-10.93%	95.31%	-50.90%	272.38%

Fundamentals

Market Cap FLGT : $489.35M CPRX : $3.15B
EPS FLGT : -$1.97 CPRX : $1.68
PS Ratio FLGT : 1.52 CPRX : 5.35
PB Ratio FLGT : 0.44 CPRX : 3.30
Total Revenue (TTM) FLGT : $322.67M CPRX : $588.99M
Gross Profit (TTM) FLGT : $130.88M CPRX : $726.82M
EBITDA (TTM) FLGT : -$45.71M CPRX : $257.78M

Returns By Period

In the year-to-date period, FLGT achieves a -39.47% return, which is significantly lower than CPRX's 6.08% return.

FLGT

• 1D: 1.73%
• 1M: 3.72%
• YTD: -39.47%
• 6M: -29.65%
• 1Y: -5.92%
• 3Y*: -20.14%
• 5Y*: -30.83%
• 10Y*: —

CPRX

• 1D: 4.12%
• 1M: 7.28%
• YTD: 6.08%
• 6M: 25.69%
• 1Y: 2.10%
• 3Y*: 14.30%
• 5Y*: 40.58%
• 10Y*: 35.35%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

FLGT vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FLGT

FLGT Risk / Return Rank: 38
FLGT Sharpe Ratio Rank: 37
FLGT Sortino Ratio Rank: 38
FLGT Omega Ratio Rank: 41
FLGT Calmar Ratio Rank: 38
FLGT Martin Ratio Rank: 36

CPRX

CPRX Risk / Return Rank: 41
CPRX Sharpe Ratio Rank: 44
CPRX Sortino Ratio Rank: 38
CPRX Omega Ratio Rank: 37
CPRX Calmar Ratio Rank: 42
CPRX Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FLGT vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FLGT	CPRX	Difference
Sharpe ratio Return per unit of total volatility	-0.10	0.06	-0.16
Sortino ratio Return per unit of downside risk	0.31	0.32	-0.01
Omega ratio Gain probability vs. loss probability	1.06	1.04	+0.02
Calmar ratio Return relative to maximum drawdown	-0.12	0.01	-0.13
Martin ratio Return relative to average drawdown	-0.37	0.02	-0.39
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

FLGT vs. CPRX - Sharpe Ratio Comparison

The current FLGT Sharpe Ratio is -0.10, which is lower than the CPRX Sharpe Ratio of 0.06. The chart below compares the historical Sharpe Ratios of FLGT and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	FLGT	CPRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.10	0.06	-0.16
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.60	0.85	-1.44
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.56	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	0.08	0.00

Correlation

The correlation between FLGT and CPRX is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

FLGT vs. CPRX - Dividend Comparison

Neither FLGT nor CPRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

FLGT vs. CPRX - Drawdown Comparison

The maximum FLGT drawdown since its inception was -92.50%, roughly equal to the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for FLGT and CPRX.

Drawdown Indicators

	FLGT	CPRX	Difference
Max Drawdown Largest peak-to-trough decline	-92.50%	-94.25%	+1.75%
Max Drawdown (1Y) Largest decline over 1 year	-55.30%	-27.29%	-28.01%
Max Drawdown (5Y) Largest decline over 5 years	-87.56%	-45.37%	-42.19%
Max Drawdown (10Y) Largest decline over 10 years	—	-64.87%	—
Current Drawdown Current decline from peak	-91.35%	-5.89%	-85.46%
Average Drawdown Average peak-to-trough decline	-61.02%	-52.51%	-8.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.10%	15.10%	+3.00%

Volatility

FLGT vs. CPRX - Volatility Comparison

Fulgent Genetics, Inc. (FLGT) has a higher volatility of 11.12% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 10.39%. This indicates that FLGT's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	FLGT	CPRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.12%	10.39%	+0.73%
Volatility (6M) Calculated over the trailing 6-month period	56.36%	23.71%	+32.65%
Volatility (1Y) Calculated over the trailing 1-year period	59.62%	34.96%	+24.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	51.89%	48.24%	+3.65%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.13%	62.81%	+13.32%

Financials